Melanie Szweras and Patrick Roszell talk AI and Health Privacy with Lexpert
Recently Smart & Biggar Principals Patrick Roszell and Melanie Szweras sat down with Lexpert’s Zena Olijnyk to discuss the privacy impacts caused by the increasing use of artificial intelligence (AI) in the healthcare sector.
Melanie raised a few key privacy concerns, including the fact the someone’s “highly sensitive” health information could be improperly disclosed or misused, and whether data used in the health and life sciences sector has been properly anonymized. Of these concerns she notes “the key issue becomes the balance between the duty to protect personal health information and the ability to manage information in the healthcare system.”
Patrick discussed the touchpoints data has between acquisition and use and how parties along the way seek to impose restrictions or assert rights on how the data is used, noting “organizations are going to need to become more sophisticated about how they understand the importance of these rights, and how they contract around them.” He also noted that organizations need to understand both the technical aspects and the privacy considerations and that “technically-minded lawyers can do a lot to bring valuable guidance in connecting these dots.”
Read the full Lexpert interview.
Related News & Media
-
Graham Hood on Canadian brand owners’ response to US trade policies
Recently, Graham Hood, the firm’s Trademarks Practice Group Leader, spoke with Rani Mehta of Managing IP about Canadian brand owners’ response to the US political climate.Read More -
Melanie Szweras on certifying data breach class actions for Lexpert
Recently, Principal Melanie Szweras spoke with Jessica Mach from Lexpert on some of the challenges that arise in certifying data breach class actions.Read More -
Noel Courage quoted in Lexpert on licensing gains as patent expiries loom
Smart & Biggar Principal Noel Courage recently discussed licensing trends with Lexpert, noting that start-ups and academic institutions remain key innovation sources in the pharma and biopharmaceu...Read More